Clinical trial
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head…
NCT00089297 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00089297 |
|---|---|
| Title | Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
| Official title | Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | Cetuximab, Carboplatin, Paclitaxel, Radiation therapy |
| Enrollment | 74 |
| Start date | Jan 6, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2011 |
| First posted | Aug 5, 2004 |
| Last update posted | Jun 29, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: